IP Library Patent Application 18205399
Patent Application
App. No. 18/205,399

Hemostatic Foam

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/205,399
Abstract

The invention is directed a hemostatic foam, to a process for preparing a biodegradable hemostatic foam, and to the use of said foam. The hemostatic foam comprises a blend of a chitosan hemostatic agent and a polymer, which polymer provides the foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm 3 .

Claims (36)

1 . Hemostatic foam comprising a blend of a chitosan hemostatic agent and a polymer, which polymer provides the foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm 3 , wherein the foam density is calculated as the polymer mass per volume unit foam.

2 - 17 . (canceled)

18 . A hemostatic foam according to claim 1 , wherein the amount of said chitosan hemostatic agent is from 0.1 to 99 wt. % of the total weight of said hemostatic foam.

19 . A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent is present in said hemostatic foam in the form of particles.

20 . A hemostatic foam according to claim 19 , wherein said particles have a size from 1-1000 μm.

21 . A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent is chitosan or a chitosan salt.

22 . A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent has a degree of deacetylation of 1-100 mol %.

23 . A hemostatic foam according to claim 1 , wherein said polymer is selected from the list consisting of polyesters, polyhydroxyacids, polylactones, polyetheresters, polycarbonates, polydioxanes, polyanhydrides, polyurethanes, polyester(ether)urethanes, polyurethane urea, polyamides, polyesteramides, poly-orthoesters, polyaminoacids, polyphosphonates, polyphosphazenes and combinations thereof.

24 . A hemostatic foam according to claim 1 , wherein said polymer is a phase-separated polymer comprising an amorphous segment and a crystalline segment, wherein at least said amorphous segment comprises a hydrophilic segment.

25 . A hemostatic foam according to claim 8 , wherein said phase-separated polymer is of formula (I):

[-R-Q 1 [-R′-Z 1 -[R″-Z 2 -R′″-Z 3 ] p -R″-Z 4 ] q -R′-Q 2 -] n   (I)

wherein:

R is a polymer or copolymer selected from one or more aliphatic polyesters, polyether esters, polyethers, polyanhydrides, and/or polycarbonates, and at least one R comprises the hydrophilic segment;

R′, R″ and R′″ are independently C 2 -C 8 alkylene, optionally substituted with C 1 -C 10 alkyl or C 1 -C 10 alkyl groups substituted with protected S, N, P or O moieties and/or comprising S, N, P or O in the alkylene chain;

Z 1 -Z 4 are independently amide, urea or urethane;

Q 1 and Q 2 are independently urea, urethane, amide, carbonate, ester or anhydride;

n is an integer from 5-500; and

p and q are independently 0 or 1.

26 . A hemostatic foam according to claim 1 , wherein said hemostatic agent is distributed at the boundaries of said chitosan hemostatic foam, or homogeneously throughout said hemostatic foam, or as a gradient within said hemostatic foam.

27 . A hemostatic foam according to claim 1 , wherein said hemostatic foam is bioresorbable.

28 . A hemostatic foam according to claim 1 , wherein the polymer in the blend have a degree of cross-linking of 0.01 or lower.

29 . A process for preparing a hemostatic foam, said process comprising:

dissolving a phase-separated polymer in a solvent to obtain a polymer solution;

blending a chitosan hemostatic agent with the polymer solution to form a mixture; and

removing the solvent by freeze-drying.

30 . A process for preparing a hemostatic foam, comprising said chitosan hemostatic agent particles, said process comprising:

dissolving at least one synthetic polymer in one or more solvents to form a solution;

contacting chitosan hemostatic agent particles with said solution to form a polymer/particles mixture;

freeze-drying the polymer/particles mixture by freezing the polymer/particles mixture; and

subsequently subliming the one or more solvents to form the hemostatic foam comprising said chitosan hemostatic agent particles.

31 . Biodegradable hemostatic foam obtainable by the process according to claim 29 .

32 . A method of using the hemostatic foam according to claim 1 as a hemostatic sponge, as a wound dressing material, as a packing for antrums or other cavities of the human or animal body, as a nasal dressing, as a packing for the outer ear, as a drain, in general surgery or as a drug delivery vehicle.

33 . A hemostatic foam according to claim 1 , wherein the amount of said chitosan hemostatic agent is from 2 to 50 wt. % of the total weight of said hemostatic foam.

34 . A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent is chitosan acetate.

35 . A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent has a degree of deacetylation of 5-50 mol %.

36 . A hemostatic foam according to claim 3 , wherein said particles have a size from 10-90 μm.

Assignments (1)
CHANGE OF ADDRESS Recorded Dec 18, 2024
From: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
To: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC
Reel/Frame 069730/0754 →